-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Good Therapeutics today announced that it has confirmed an acquisition agreement
Roche will have access to Good Therapeutics' innovative, conditional activation, PD-1-regulated IL-2 program, and the exclusive rights
Good focuses on developing protein therapies
Image source: Good Therapeutics
Under the M&A agreement, Roche will make an advance payment of $250 million to Good and pay the corresponding amount based on predetermined development, regulatory and commercial milestones
"Good was founded to develop a new class of drugs that can be conditionally activated, which are not only more effective, but also avoid the problems that have arisen from systemic immune activation in many of the previous drugs," said Dr.